We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly & BI Win EU Marketing Authorization for Insulin Biosimilar
Eli Lilly & BI Win EU Marketing Authorization for Insulin Biosimilar
European regulators have approved Eli Lilly and Boehringer Ingelheim’s insulin glargine drug Abasria, a biosimilar version of Sanofi’s blockbuster product Lantus.